8-K: Phoenix Biotech Acquisition Corp. Amends Merger Agreement with CERo Therapeutics, Adding Earnout Shares

Phoenix Biotech Acquisition Corp. has amended its merger agreement with CERo Therapeutics, introducing additional earnout shares and modifying vesting conditions.

Summary

• Phoenix Biotech Acquisition Corp. has modified its business combination agreement with CERo Therapeutics through Amendment No. 2.
• The amendment introduces two new pools of earnout shares: 875,000 shares that vest immediately upon closing and 1,000,000 shares that vest upon achieving specific regulatory milestones.
• The amendment also adjusts the timing and process for issuing 1,200,000 shares tied to other earn-out conditions.
• A total of 3,075,000 shares of Class A Common Stock are now part of the Company Stockholders Earn-Out Consideration.
• The earnout shares are subject to vesting requirements and forfeiture if these requirements are not met within four years of the closing date.
• Vesting of 500,000 shares each is tied to the stock price reaching certain levels ($12.50 or 125% of the Series A conversion price and $15.00 or 150% of the Series A conversion price).
• An additional 200,000 shares vest upon a change of control agreement.
• 1,000,000 shares vest upon submission of an Investigational New Drug (IND) application to the FDA.
• The amendment also addresses potential antitrust issues related to the earnout shares, including potential cash payments in lieu of shares.

Sentiment

Score: 7

Explanation: The document is generally positive, outlining an amendment to a merger agreement with additional incentives for the target company. However, it also includes risks and uncertainties related to the earnout structure and regulatory approvals.

Positives

• The amendment provides additional incentives for CERo Therapeutics to achieve key milestones.
• The immediate vesting of 875,000 shares at closing provides an upfront benefit to CERo's stockholders.
• The earnout structure aligns the interests of both companies by tying share vesting to performance and regulatory achievements.
• The inclusion of a cash payment option for antitrust issues provides flexibility and reduces potential roadblocks.

Negatives

• The earnout shares are subject to forfeiture if the vesting requirements are not met within the four-year earnout period.
• The vesting of a significant portion of shares is dependent on the stock price reaching specific targets, which may not be achieved.
• The potential for antitrust issues could delay the release of earnout shares to certain participants.

Risks

• The failure to achieve the stock price targets or regulatory milestones could result in the forfeiture of earnout shares.
• Antitrust issues could delay or complicate the release of earnout shares.
• The complexity of the earnout structure could lead to disagreements or disputes between the parties.
• The market price of the stock may not reach the required levels for vesting of the earnout shares.

Future Outlook

The document outlines the terms of the amended merger agreement, including the earnout structure and vesting conditions. The completion of the merger is subject to various conditions, including regulatory approvals and stockholder approval. The document also includes forward-looking statements regarding the potential benefits of the merger and the future performance of the combined company, but these are subject to risks and uncertainties.

Management Comments

• The parties desire to modify the Equity Value for the Company.
• The parties desire to modify the terms set forth in Section 2.1(a)(ix) of the Agreement with respect to the Company Stockholders Earn-Out Consideration.

Industry Context

This announcement is typical of SPAC mergers, where earnouts are often used to align the interests of the target company's shareholders with the performance of the combined entity. The use of regulatory milestones as vesting conditions is common in the biotech industry, reflecting the importance of clinical and regulatory progress.

Comparison to Industry Standards

• The use of earnouts in SPAC mergers is a common practice, often structured around stock price performance and key milestones.
• The vesting conditions tied to stock price targets are similar to those seen in other biotech mergers, such as the merger of Immunomedics and Gilead Sciences, where a portion of the consideration was contingent on achieving certain sales targets.
• The inclusion of regulatory milestones, such as the IND application submission, is also a standard practice in biotech deals, similar to the merger of Celgene and Bristol Myers Squibb, where regulatory approvals were key to the deal's success.
• The potential for cash payments in lieu of shares due to antitrust issues is a less common but prudent measure, reflecting the complexities of regulatory approvals in mergers, similar to the merger of Aetna and CVS, where regulatory hurdles required significant adjustments to the deal structure.

Stakeholder Impact

• Shareholders of Phoenix Biotech Acquisition Corp. will be impacted by the potential dilution from the issuance of earnout shares.
• Shareholders of CERo Therapeutics will benefit from the potential for additional shares if the earnout targets are met.
• Employees of both companies may be impacted by the merger and the integration of the two businesses.

Next Steps

• The parties will need to obtain regulatory approvals and stockholder approval to complete the merger.
• The earnout shares will vest upon the achievement of the specified stock price targets, regulatory milestones, and change of control.
• The company will need to monitor the stock price and regulatory progress to determine when the earnout shares will vest.

Key Dates

Keywords

merger, acquisition, earnout, biotech, pharmaceutical, stock, vesting, regulatory, milestone, antitrust